Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis
β Scribed by C.D. Dijkstra; E.Rouppe van der Voort; C.J.A. De Groot; I. Huitinga; B.M.J. Uitdehaag; C.H. Polman; F. Berkenbosch
- Book ID
- 113329125
- Publisher
- Elsevier Science
- Year
- 1994
- Tongue
- English
- Weight
- 522 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0306-4530
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A herbal formula, Badmaev 28, was evaluated in the treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis (EAE) in SJL/J mice. Chronic EAE was induced by immunization of 8 week old mice with an emulsion of syngeneic spinal cords with incomplete Freund'
## Abstract The ergoline derivative FCE 23884 acts as a dopamine D~1~ agonist in untreated parkinsonian animals and as a D~2~ antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have
The effects of the dopamine (DA) receptor agonists apomorphine, bromocriptine and pergolide were compared with those produced by a DA receptor antagonist, haloperidol, in rats implanted with electrodes for chronic sleep recordings. Apomorphine (0.025-2.0 mg/kg) and bromocriptine (0.25-6.0 mg/kg) ind